AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33019891
Drug: Cholecalciferol 1000-2000
RxNorm normalized name: cholecalciferol 2000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 1000-2000 IU daily or 50000 IU weekly until vitamin D levels >20 ng/mL (group IIa)
Trial: 32898192
Drug: Aceclofenac 100
RxNorm normalized name: aceclofenac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac 100 mg tablet formulation (F-15)
Trial: 34723864
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (5 mg/kg ideal body weight)
Trial: 34674610
Drug: Standardized extract
RxNorm normalized name: Spring Valley Olive Leaf Standardized Extract 150mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized extract of Calendula officinalis L. (SEC)
Trial: 32187097
Drug: Local multimodal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local multimodal drug injection (ropivacaine 10 mL, morphine 5 mL, ceftezole 5 mL, normal saline 5 mL)
Trial: 32187097
Drug: Local multimodal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local multimodal drug injection
Trial: 33935137
Drug: New drug
RxNorm normalized name: varicella zoster immune globulin (Investigational New Drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drug comorbidity index
Trial: 33962902
Drug: Daily delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily delivery of a single whole egg per day added to local standard nutrition care for 6 months
Trial: 33165153
Drug: Multimodal neuroimaging-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal neuroimaging-based customized TMS treatment
Trial: 36457068
Drug: Esketamine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine 0.2 mg/kg IV before induction of anesthesia
Trial: 34186473
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medications including opioids and other medications inconsistent with national (NICE) guidance
Trial: 32107712
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg daily)
Trial: 35690073
Drug: 3‐weekly carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐weekly carboplatin AUC5 or AUC6 and 3‐weekly paclitaxel 175 mg/m2 (control; group 1)
Trial: 35690073
Drug: 3‐weekly carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐weekly carboplatin AUC5 or AUC6 and weekly paclitaxel 80 mg/m2 (group 2)
Trial: 35690073
Drug: Weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly carboplatin AUC2 and weekly paclitaxel 80 mg/m2 (group 3)
Trial: 32170964
Drug: Initial cohort
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial cohort (no treatment)
Trial: 37481816
Drug: Optimal Medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Medical Therapy (OMT)
Trial: 34480787
Drug: USPIO injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USPIO injection (5.6 mg/kg)
Trial: 34480787
Drug: USPIO injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USPIO injection (16.8 mg/kg)
Trial: 34480787
Drug: USPIO injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USPIO injection (56 mg/kg)
Trial: 34812502
Drug: Baseline GDF15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline GDF15 >1350 pg/mL
Trial: 34812502
Drug: AFP >5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFP >5 ng/mL
Trial: 32511015
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy interventions for anxiety
Trial: 32511015
Drug: Pre-treatment accommodation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment accommodation
Trial: 36774994
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of ranibizumab
Trial: 33814126
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 10 mg/day
Trial: 36008795
Drug: Myofunctional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofunctional treatment (MB-M group)
Trial: 36008795
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (MB-N group)
Trial: 36008795
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (NB group)
Trial: 35295986
Drug: Liothyronine 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liothyronine 0.7 mcg/kg
Trial: 35295986
Drug: Levothyroxine 0.86
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine 0.86 mcg/kg
Trial: 34898075
Drug: Linshu Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linshu Decoction (1 dose bid) combined with levofloxacin (0.1 g bid)
Trial: 34898075
Drug: Levofloxacin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (0.1 g bid)
Trial: 33407619
Drug: Peg-interferon treatment
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-interferon treatment
Trial: 32220093
Drug: Type 2
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 2 statins (atorvastatin, rosuvastatin)
Trial: 32745598
Drug: Family Focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Focused Therapy for High-Risk Youth (FFT-HR)
Trial: 33725579
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical, MRI, and pathology features
Trial: 34609956
Drug: Directly Observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Observed Treatment (DOT)
Trial: 32402630
Drug: Complex decongestive
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex decongestive therapy (CDT) combined with rehabilitation exercise
Trial: 37074613
Drug: Remdesivir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remdesivir (200 mg on day 1 and 100 mg on days 2 and 3)
Trial: 32278106
Drug: Interrupted Subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted Subcutaneous Suture Group
Trial: 33159033
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (IN‐OT) treatment (24 IU daily for 4 weeks)
Trial: 33159033
Drug: Multiple-dose IN‐OT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose IN‐OT treatment (24 IU daily for 4 weeks)
Trial: 32991355
Drug: Carvedilol 12.5
RxNorm normalized name: carvedilol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5 mg/d
Trial: 32978034
Drug: Enriched Acceptance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enriched Acceptance and Commitment Therapy (EnACT)
Trial: 33678038
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention administered by an unblinded nurse falls care manager
Trial: 35313936
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.25% bupivacaine (total 50 mg) for bilateral ultrasound-guided rectus sheath block (URSB)
Trial: 33580845
Drug: Glutamine (4
RxNorm normalized name: N5-((2E)-((2-(((2,3-bis(omega-methoxypoly(oxyethylene))propoxy)carbonyl)amino)ethoxy)imino)ethyl)glutamine (43000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (4 g twice daily)
Trial: 33580845
Drug: Placebo (glycine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glycine, 4 g twice daily)
Trial: 33584534
Drug: Gabby (online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabby (online conversational agent)
Trial: 35357881
Drug: Propranolol (β-blocker)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (β-blocker)
Trial: 37615850
Drug: Ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 mg daily
Trial: 35381657
Drug: Psychological suggestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological suggestion combined with rational diet therapy
Trial: 34313371
Drug: Ripretinib 150
RxNorm normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ripretinib 150 mg b.i.d.
Trial: 33037609
Drug: Medium NaCl
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium NaCl (0.4 g/100 mL) + 29 mM MSG
Trial: 33037609
Drug: Low NaCl
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low NaCl (0.2 g/100 mL) + 29 mM MSG
Trial: 33037609
Drug: Control broth
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control broth (0 g NaCl, 0 g MSG)
Trial: 33037609
Drug: High NaCl
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NaCl broth (0.8 g/100 mL)
Trial: 33037609
Drug: Medium NaCl
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium NaCl (0.4 g/100 mL)
Trial: 33037609
Drug: Low NaCl
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low NaCl (0.2 g/100 mL)
Trial: 33718425
Drug: Insulin-resistant group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant group
Trial: 33718425
Drug: Insulin-sensitive group
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-sensitive group
Trial: 33938708
Drug: Tacrolimus 0.1%
RxNorm normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.1% ointment after dermabrasion
Trial: 33938708
Drug: Dinoprostone gel
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone gel after dermabrasion
Trial: 34670544
Drug: Microthreaded implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microthreaded implants
Trial: 34670544
Drug: Threaded implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threaded implants
Trial: 35272779
Drug: Intravascular ultrasound
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular ultrasound (IVUS) guidance with drug-coated balloons
Trial: 35272779
Drug: Angiographic guidance
RxNorm normalized name: Andrographis paniculata top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiographic guidance with drug-coated balloons
Trial: 36894938
Drug: Dulaglutide 4.5
RxNorm normalized name: DULAGLUTIDE 4.5MG/0.5ML INJ PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 4.5 mg
Trial: 35546790
Drug: Dulaglutide 3.0
RxNorm normalized name: Dulaglutide 3.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [Trulicity]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 3.0 mg
Trial: 34386735
Drug: Dapagliflozin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 50 mg
Trial: 34281014
Drug: Live-Performed Music
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-Performed Music Therapy (LPMT)
Trial: 33377343
Drug: CO2 fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 fractional laser treatment
Trial: 36380186
Drug: B. clausii
DrugBank: Bacillus clausii (DB16537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B. clausii (oral suspension, total dose 4 billion spores/day)
Trial: 32224739
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) at a dose of 15 mg/kg
Trial: 34932280
Drug: Mexidol intravenously
RxNorm normalized name: Brexidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol intravenously 500 mg once daily for 14 days, followed by Mexidol FORTE 250 - 250 mg 3 times a day orally for 60 days
Trial: 34399839
Drug: Polyvinyl chloride
RxNorm normalized name: POLYVINYL CHLORIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvinyl chloride foil containing an integrated silver-based agent (2% silver ions) applied to high-touch surfaces
Trial: 33377959
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy
Trial: 36378780
Drug: Udenafil (87.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil (87.5 mg po BID)
Trial: 32795214
Drug: Ongoing medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing medicine randomized controlled trials (RCTs) in Europe
Trial: 32795214
Drug: Ongoing medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing medicine randomized controlled trials (RCTs) in the USA
Trial: 33594278
Drug: Scheduled low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Scheduled low-dose memory (CD45RA-depleted) donor lymphocyte infusion (mDLI)
Trial: 33086387
Drug: Intra-arterial short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-arterial short-term infusion chemotherapy via angiocatheters or implanted arterial port catheters, infusion time of 7 to 12 minutes.
Trial: 34958721
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (5.8%) injection
Trial: 34958721
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (0.9%) injection
Trial: 34704715
Drug: Medial branch
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medial branch block (MBB) during PKP surgery, injection of lidocaine and budesonide
Trial: 34704715
Drug: Non-MBB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-MBB group (normal saline injection during PKP surgery)
Trial: 35416374
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of induction chemotherapy with platinum and docetaxel (TP) plus a Bcl‐2 inhibitor
Trial: 35416374
Drug: Single cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cycle induction chemotherapy with platinum and 5‐flurouracil (PF)
Trial: 35781776
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy
Trial: 32758152
Drug: Manufactured UDCA
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured UDCA (300 mg tablets and capsules)
Trial: 37699636
Drug: Oral hydration
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydration
Trial: 85068751
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 + 2.5 mg
Trial: 85068751
Drug: Ethanol (1
RxNorm normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (1 g/kg)
Trial: 35523116
Drug: Cissus quadrangularis
RxNorm normalized name: Cissus quadrangularis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cissus quadrangularis 1.6 g/day (CQ1.6)
Trial: 35523116
Drug: Cissus quadrangularis
RxNorm normalized name: Cissus quadrangularis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cissus quadrangularis 1.2 g/day (CQ1.2)
Trial: 34978133
Drug: PRP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP treatment (all groups)
Trial: 32621657
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid injections using a stamp-type microneedle (Dermashine balance)
Trial: 38394657
Drug: Leukocyte- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte- and platelet-rich fibrin (L-PRF)
Trial: 36151016
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no L-PRF)
Trial: 37778356
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment
Trial: 36450853
Drug: Oral 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 10% dextrose
Trial: 33615641
Drug: 10 mM
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mM denatonium benzoate solution (0.1 ml/kg)
Trial: 35262718
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose aspirin (81 mg) taken at least 5 of 7 days per week for at least 80% of follow-up time
Trial: 35894657
Drug: C21 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 (200 mg)
Trial: 36327320
Drug: daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral PrEP
Trial: 36327320
Drug: daily Truvada
RxNorm normalized name: Truvada
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: daily Truvada
Trial: 32687819
Drug: Behavioral weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral weight loss intervention (health coaching phone sessions weekly for 6 months, then monthly for 18 months or until end of pregnancy)
Trial: 33691499
Drug: M. vaccae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. vaccae in combination with standard care
Trial: 36083814
Drug: Daily intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intravenous infusions of ozonized saline with ozone concentration of 2.0 mg/l for 5 days followed by standard rehabilitation (n=18)
Trial: 36083814
Drug: 5 ozone
RxNorm normalized name: OZONE
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ozone therapy procedures every other day (n=16)
Trial: 36083814
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with a 10-day course of daily breathing exercises and physiotherapy for the lungs (n=17)
Trial: 35534091
Drug: Capsules
RxNorm normalized name: VG capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: 35925157
Drug: PMD200 monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PMD200 monitoring with sufentanil bolus administered when NoL index > 25 for 2 min (n=24)
Trial: 35925157
Drug: Standardized sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized sufentanil bolus administered at anesthesiologist's discretion (n=26)
Trial: 32222430
Drug: Definitive thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definitive thoracic radiation therapy (RT) administered once or twice daily for LS-SCLC
Trial: 32222430
Drug: Involved field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved field RT using conformal advanced treatment modalities to postchemotherapy volumes
Trial: 32222430
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) or conventional fractionation for stage I or II node negative disease
Trial: 32222430
Drug: Thoracic RT
RxNorm normalized name: CATH,THORACIC RT ANGLE 28FR K#573048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic RT in select patients with ES-SCLC after chemotherapy treatment
Trial: 34388698
Drug: Palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (125 mg/d on a 3 weeks on/1 week off schedule) plus letrozole (2.5 mg/d, continuous)
Trial: 33801216
Drug: Wearable focal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable focal muscle vibration (FMV) therapy applied using a modified MyovoltTM device, 3 days a week for 4 weeks
Trial: 33801216
Drug: Wearable focal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable focal muscle vibration (FMV) therapy
Trial: 35655286
Drug: Zhizhu Kuanzhong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhizhu Kuanzhong Capsule (ZZKZ)
Trial: 33610123
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with concurrent cediranib, followed by maintenance cediranib (arm C)
Trial: 33610123
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with concurrent cediranib, followed by maintenance placebo (arm B)